# OnCo record destiny-crc01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/destiny-crc01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "destiny-crc01", "NCT03384940" ;
  schema:name "DESTINY-CRC01"@en ;
  schema:description "The first trial of the HER2 antibody-drug conjugate in bowel cancer. Almost half the strongly HER2-positive tumours shrank, including some that had already failed other HER2 drugs."@en ;
  schema:url <https://onco.cc/trials/destiny-crc01/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03384940>, <https://doi.org/10.1016/S1470-2045(21)00086-3> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/her2-amplified-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/destiny-crc02/>, <https://onco.cc/trials/mountaineer/> .